LOGIN  |  REGISTER
Viking Therapeutics

Electromed to Participate in Upcoming Investor Conferences

February 26, 2025 | Last Trade: US$24.10 1.17 -4.63

NEW PRAGUE, Minn. / Feb 26, 2025 / Business Wire / Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that management will participate in the following upcoming investor conferences:

The Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

  • Management will present at 10:30 a.m. Eastern Time on Tuesday, March 18, 2025. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations. Interested parties may also access the live webcast here. Investors may request meetings through their Oppenheimer representative.

The Sidoti Virtual Small-Cap Conference

  • Management will present at 1:45 p.m. Eastern Time on Thursday, March 20, 2025. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations.

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page